Skip to content

Clinical observation of Wumei formula granules regulating Glu/GABA-Gln metabolic circuit and HPA axis in the treatment of insomnia in Jueyin syndrome

Clinical observation of Wumei formula granules regulating Glu/GABA-Gln metabolic circuit and HPA axis in the treatment of insomnia in Jueyin syndrome

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100047866
Enrollment
Unknown
Registered
2021-06-27
Start date
2021-07-01
Completion date
Unknown
Last updated
2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

insomnia

Interventions

Sponsors

the Second Affiliated Hospital of Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-70 years old; 2. Meet the diagnostic criteria of traditional Chinese medicine and the diagnostic criteria of western medicine for insomnia; 3. Sign the informed consent and voluntarily join the clinical research observation; 4. Be able to understand the research content and have normal communication and comprehension skills; 5. Have not used related drugs for the treatment of insomnia, including traditional Chinese medicine, proprietary Chinese medicine and western medicine in the past 1 week.

Exclusion criteria

Exclusion criteria: 1. Those who are allergic to umeboshi formula granules; 2. Exclude organic brain diseases: such as Parkinson's, dementia, cerebrovascular disease, etc.: exclude insomnia caused by organic diseases: such as restless legs syndrome, periodic limb movements, OSAS, parasomnia, hypothyroidism, Hyperthyroidism, alcohol dependence, etc. 3. There are obvious systemic pain, fever and infection and other diseases; 4. Patients with insomnia due to obvious environmental interference or due to alcohol, coffee, drug dependence or mental disorders; 5. Those who are currently taking drugs that affect sleep structure.

Design outcomes

Primary

MeasureTime frame
GABA;Glutamate;adrenocorticotropic hormone;cortisol hormone;

Countries

China

Contacts

Public ContactYao Wei

the Second Affiliated Hospital of Dalian Medical University

411484335@qq.com+86 17709877386

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026